New eczema drug shows promise in early trial

NCT ID NCT07502222

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Apr 11, 2026 · Last updated May 15, 2026 · Updated 7 times

Summary

This study tests a new medicine called AK139 for people with moderate to severe atopic dermatitis (eczema). About 168 adults will receive either AK139 or a placebo to see if it safely improves skin symptoms like itching and redness. The trial is in Phase 2 and is not yet recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.